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The lncRNA landscape of breast cancer reveals
a role for DSCAM-AS1 in breast cancer progression
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Michael Uhl9, Alexander Gawronski10, Daniel F. Hayes5,6,11, Lori J. Pierce3,5,6, Xuhong Cao1,8, Colin Collins13,
Rolf Backofen9, Cenk S. Sahinalp10,12,13, James M. Rae5,6,11, Arul M. Chinnaiyan1,2,5,6,8,14,15,**
& Felix Y. Feng1,3,5,6,**,w
Molecular classification of cancers into subtypes has resulted in an advance in our
understanding of tumour biology and treatment response across multiple tumour types.
However, to date, cancer profiling has largely focused on protein-coding genes, which
comprise o1% of the genome. Here we leverage a compendium of 58,648 long noncoding
RNAs (lncRNAs) to subtype 947 breast cancer samples. We show that lncRNA-based
profiling categorizes breast tumours by their known molecular subtypes in breast cancer.
We identify a cohort of breast cancer-associated and oestrogen-regulated lncRNAs,
and investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA,
DSCAM-AS1. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen
resistance and identify hnRNPL as an interacting protein involved in the mechanism of
DSCAM-AS1 action. By highlighting the role of DSCAM-AS1 in breast cancer biology and
treatment resistance, this study provides insight into the potential clinical implications of
lncRNAs in breast cancer.
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L
ong noncoding RNAs (LncRNAs) have recently been
implicated in a variety of biological processes, including
carcinogenesis and tumour growth1–6. Operating through a
myriad of mechanisms2, lncRNAs have challenged the central
dogma of molecular biology as prominent functional RNA
molecules. To investigate the role of lncRNAs in breast cancer,
we interrogated the expression of lncRNAs across an
RNA-sequencing (RNA-seq) breast tissue cohort comprised of
947 breast samples7,8. Previously, in a large-scale ab initio meta-
assembly study from 6,503 RNA-seq libraries, we discovered
B45,000 of unannotated human lncRNAs7, and this assembly
was utilized for the present study. Building on prior work that has
begun to investigate the role of lncRNAs in breast cancer9, we set
out to perform a comprehensive analysis of breast cancer tissue
RNA-seq data to identify the lncRNAs potentially involved in
breast cancer.
Patients with oestrogen receptor (ER)-positive breast cancer
have better prognosis than those with ER-negative disease,
based on both a more indolent natural history but perhaps
more importantly due to effective anti-oestrogen, also designated
‘endocrine,’ therapy10. Despite the efficacy of endocrine therapy,
however, the majority of breast cancer deaths occur in women
with ER-positive breast cancers, because the incidence of
ER-positive versus-negative disease is much higher
(approximately 80 versus 20%), and because a substantial
fraction of women either have inherent or acquired endocrine
therapy-resistant disease11.
Taken together, these considerations highlight the pressing
need to understand the biology of the ER-driven breast cancers
and their mechanism of resistance to endocrine therapy. The
mechanism through which ER mediates cancer initiation and
progression is an area of intense scientific investigation12–14 that
remains incompletely understood. In this regard, while
substantial research has been focused on ER abnormalities,
such as mutations in the gene encoding for ER (ESR1)14,15 and on
the co-existing activation pathways that might mediate resistance,
such as HER216, few studies exist that interrogate ER-regulated
noncoding RNAs17–21. Therefore, we set out to perform a
comprehensive discovery and investigation of those lncRNAs that
are driven by oestrogen in breast cancers drawing from a large
human tissue RNA-seq cohort.
Results
Identification of ER- and breast cancer-associated lncRNAs.
We initially focused on those lncRNAs most differentially
expressed in breast cancers in comparison to benign adjacent
tissue (Supplementary Data 1), utilizing a non-parametric dif-
ferential expression tool for RNA-seq called Sample Set Enrich-
ment Analysis (SSEA)7. After applying an expression filter (at
least one fragments per kilobase of transcript per million mapped
reads (FPKM) expression in the breast samples in the top 5%
based on gene expression level), we identified 437 of the most
differentially expressed lncRNAs in breast cancer (Supplementary
Data 2). Interestingly, unsupervised hierarchical clustering of the
samples based on expression of these lncRNAs across all breast
cancer samples (Methods section) largely separated out the breast
cancer samples by PAM50 subtypes22,23, suggesting that lncRNAs
may be contributing to the distinct biology of these subtypes
(Fig. 1a). While lncRNA expression was unable to distinguish
between the ER-driven luminal A and luminal B subtypes, the
luminal subtypes were well separated from the HER2, basal and
normal subtypes (Fig. 1a). In addition to separating out the
clinical subtypes of breast cancer, the lncRNAs themselves
separated into three distinct clusters. The first cluster (Fig. 1a,
‘Luminal’) contains lncRNAs overexpressed mostly in luminal A
and luminal B samples, with little expression in samples of the
other subtypes, and little expression in normal samples. The next
cluster contains lncRNAs upregulated across all breast cancer
samples (Fig. 1a, ‘Upregulated’), and this cluster included the
known breast cancer lncRNA, HOTAIR. The third cluster
(Fig. 1a, ‘Downregulated’) contains lncRNAs downregulated in
breast cancers. The lncRNAs in the luminal cluster present a
particularly intriguing class of potentially oestrogen-responsive
lncRNAs.
Using the 947 breast tumour RNA-seq samples
(Supplementary Data 1), we identified lncRNAs differentially
expressed in ER-positive versus ER-negative breast tumours
(Fig. 1b, Supplementary Data 2). As expected, the expression of
lncRNAs differentially expressed in ER-positive tumours
separated the luminal tumours from the basal and HER2 on
unsupervised hierarchical clustering (Fig. 1b). Quite interestingly,
a number of lncRNAs that were downregulated in ER-positive
samples exhibited increased expression in the basal samples
(Fig. 1b, ‘Basal lncRNAs’). While these basal lncRNAs were
identified in an ER-positive versus ER-negative cancer analysis, a
number of them also exhibit low expression in normal breast
tissue (Supplementary Fig. 1). Given that a paucity of known
driver genes exist for basal breast cancers and that these tumours
are the most clinically aggressive, these basal-specific lncRNAs
may represent an exciting future area for basal breast cancer
biology.
We set out to investigate potentially oncogenic ER-regulated
lncRNAs by intersecting the lncRNAs upregulated in both
the cancer versus normal (Fig. 1a) and ER-positive versus
ER-negative (Fig. 1b) analyses. Sixty-three lncRNAs were
upregulated in both the cancer versus normal analysis and the
ER-positive versus ER-negative analysis (Supplementary Data 2,
Fig. 1c). To prioritize the most biologically and clinically relevant
lncRNAs, we focused on lncRNAs most highly expressed in
breast cancer tissues, and those most directly regulated by ER,
based on ER binding to the targets’ promoter as well as the degree
of induction of expression following oestrogen stimulation in
breast cancer cells (Fig. 1c and Supplementary Fig. 2a). This
approach nominated DSCAM-AS1 as a lncRNA expressed at a
very high level in breast cancer tissues, containing ER promoter
binding, and exhibiting the strongest oestrogen induction in
MCF7 and T47D cells by both RNA-seq and quantitative PCR
(qPCR) validation (Fig. 1c and Supplementary Fig. 2a). We thus
selected DSCAM-AS1 for further investigation.
Characterization of DSCAM-AS1. DSCAM-AS1 has been
previously reported to be involved in the proliferation of a
luminal breast cancer cell line20. It exhibits a highly cancer-
specific expression pattern, mostly in breast cancer and lung
adenocarcinoma, in transcriptome sequencing data from a cohort
of 6,503 cancer and normal tissues and cell lines from the TCGA
and the Michigan Center for Translation Pathology7 (Fig. 2a).
Supporting its association with ER biology, DSCAM-AS1
expression is highly enriched (Student’s t-test, P valueo10E 5)
in ER-positive tumours among the breast cancer samples in this
RNA-seq cohort with ER status determined by IHC (Fig. 2b and
Supplementary Data 1). In addition, analysis of RNA-seq
performed on 50 breast cancer cell lines24 revealed that
expression of DSCAM-AS1 is highly specific to ER-positive cell
lines (Fig. 2c and Supplementary Fig. 2b). Further supporting
the association of ER with DSCAM-AS1, ER chromatin
immunoprecipitation-sequencing (ChIP-seq) in both MCF7 and
T47D identified ER binding to the DSCAM-AS1 promoter
following oestrogen stimulation (Fig. 2d), and this finding
was confirmed by ChIP-qPCR of the DSCAM-AS1 promoter
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(Supplementary Fig. 2c). The isoforms of DSCAM-AS1 in
MCF7 cells were identified using 30 and 50 RACE (Fig. 2d and
Supplementary Table 1). DSCAM-AS1 expression is induced in
both MCF7 and T47D cells after oestrogen stimulation, and this
induction is reversed with addition of tamoxifen, corroborating
that ER is in fact regulating the expression of this lncRNA
(Fig. 2e). Expression of known ER-regulated protein-coding
genes GREB1 and PGR follow the same pattern of response to
oestrogen, while the lncRNA MALAT1, serving as a negative
control, is not induced by oestrogen (Fig. 2e). In addition to
being oestrogen-responsive, DSCAM-AS1 expression is present
in both the cytoplasm and nucleus at nearly identical fractions
in both MCF7 and T47D cells (Supplementary Fig. 2d), and the
identity of DSCAM-AS1 as a noncoding gene was corroborated
using the CPAT tool25 (Supplementary Fig. 2e). We used
single-molecule fluorescence in situ hybridization (ISH) to
further dissect the subcellular localization and gene expression
levels of DSCSM-AS1 in breast cancer cells. To this end, we
designed probes that targeted all potential isoforms of the
transcript predicted by RACE. On staining, we found that each
MCF7 cell expressed B800 copies of the DSCAM-AS1
transcript, almost half as much as the expression level of
GAPDH (Supplementary Fig. 2f,g), additionally the similar
nuclear and cytoplasmic localization was corroborated by ISH
(Supplementary Fig. 2h). While the abundance of DSCAM-AS1
was lower in T47D cells (B260 molecules per cell, Supple-
mentary Fig. 2i,j), the relative expression level (compared with
GAPDH) and the subcellular localization pattern were very
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Figure 1 | Identification of ER and breast cancer-associated lncRNAs. (a) Heatmap depiction of the top cancer versus normal differentially expressed
lncRNAs among the TCGA breast RNA-seq cohort (n¼ 946). 437 lncRNAs were differentially expressed with an SSEA FDRo1e-5 and an SSEA percentile
cutoff of 0.975 (Methods section). Expression values are depicted as log2 of the fold change over the median of the normal samples (n¼ 104).
Unsupervised hierarchical clustering was done on both lncRNAs and patients. Cancer progression, PAM50 classification, and ER, PR, and HER2 status are
shown above heatmap. LncRNAs clustered into 3 distinct categories, ‘Luminal’, ‘Upregulated’, and ‘Downregulated’. Two representative lncRNAs are
highlighted. (b) Heatmap depiction of the top ER-positive versus ER-negative lncRNAs. 449 lncRNAs met the SSEA criteria described in a. Unsupervised
clustering was performed for samples and lncRNAs. Expression values depicted as log2 of the fold change over the median of the ER-negative samples
(n¼ 538). Cancer progression, PAM50 classification, and ER, PR and HER2 status are shown above heatmap. One representative lncRNA is highlighted
along with a group of lncRNAs with basal-specific expression. (c) Venn diagram of the intersection of the breast cancer versus normal and ER-positive
versus ER-negative analyses. Intersection is shown for the overexpressed lncRNAs in both categories. The top 10 lncRNAs based on expression level in
breast cancer tissues (expression value of 95th percentile sample) are depicted in table. ER promoter binding determined via ChIP-seq is depicted (in either
MCF7, T47D cell lines, or both) along with expression response from RNA-seq following 3 h of oestrogen stimulation in MCF7 cells (one arrow represents
41.5 fold increase, three arrows represents 42.5 fold increase).
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similar to those observed in MCF7 cells (Supplementary
Fig. 2k).
DSCAM-AS1 is implicated in cancer aggression. We next
investigated the clinical relevance of DSCAM-AS1. Given that
DSCAM-AS1 is a lncRNA, its expression is not measured by
most traditionally used microarrays, which are the primary
high-throughput platforms annotated with reliable clinical out-
comes in breast cancer26. As a surrogate, we employed a guilt-by-
association analysis to interrogate the clinical relevance of those
genes most correlated to DSCAM-AS1. Given that DSCAM-AS1 is
an ER-regulated lncRNA, correlation was performed using only
ER-positive breast cancers, to ascertain clinical relevance in the
breast cancer samples in which DSCAM-AS1 would be enriched
and most relevant. We obtained a number of breast cancer
clinical data sets from Oncomine27 containing gene expression
sets associated with the presence of cancer (versus normal tissue),
high clinical grade, recurrence, survival and metastasis22,23,26–40
(Methods section). We assessed for the overlap between these
gene sets with the genes most positively or negatively correlated
to DSCAM-AS1. DSCAM-AS1 positively correlated genes were
significantly associated with clinical signatures associated with
increased cancer aggression, tamoxifen resistance, higher grade,
stage and metastasis (Fig. 3a,b, Supplementary Data 3 and 4).
Similarly, the DSCAM-AS1 negatively correlated genes associated
with clinical signatures that portended a more favourable clinical
outcome (Supplementary Fig. 3a,b, Supplementary Data 3 and 4).
For many of the clinical concepts, DSCAM-AS1 positively
correlated genes displayed a clinical association comparable to
those genes most correlated to EZH2, a gene known to be a
marker of clinical aggressiveness in breast cancer41, while genes
correlated to other lncRNAs expressed in breast tissue,
such as HOTAIR, MALAT1 and NEAT1, showed modest-to-no
association (Fig. 3b, Supplementary Fig. 3b, Supplementary
Data 3 and 4). In addition, performing a Gene Set Enrichment
Analysis (GSEA)42 on all genes correlated to DSCAM-AS1 yielded
significant association with a myriad of breast cancer, cancer
aggressiveness, and ER- and tamoxifen-associated gene signatures
(Supplementary Fig. 3c). While ER-positive breast cancers
typically result in better clinical outcomes23, among the luminal
breast cancers, DSCAM-AS1 is expressed significantly higher in
luminal B, a clinical subtype containing most of the clinically
aggressive ER-positive breast cancers22,23 (Fig. 3c). Despite these
associations of clinical aggression with DSCAM-AS1, in a survival
analysis of the ER-positive TCGA breast samples, expression of
DSCAM-AS1 was not significantly associated with clinical
outcome (Supplementary Fig. 3d). Definitive assessment of
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P¼0.006) (d) Incucyte proliferation assay performed following knockdown of DSCAM-AS1 using two independent shRNAs. Degree of knockdown
determined by qPCR shown above. Error bars represent the s.e.m. for three biological replicates. *Po0.01, **Po0.001, ***Po0.0001, NS: P40.01
comparing to shControl for each condition via Student’s t-test. (e) Invasion assay following shRNA knockdown of DSCAM-AS1 using Matrigel coated
Boyden chamber assay. Error bars represent the s.e.m. for three biological replicates. *Po0.01, **Po0.001, ***Po0.0001 comparing to shControl for each
condition via Student’s t-test. (f) Soft agar colony formation assay following shRNA knockdown of DSCAM-AS1. Error bars represent the s.e.m. for
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comparing to vector overexpression via Student’s t-test. (h) Mouse xenograft study of tumour growth for T47D cells with shRNA knockdown of
DSCAM-AS1. Xenografts with shRNA knockdown of DSCAM-AS1 (n¼ 24) exhibited reduced growth when compared to control shRNA knockdown (n¼ 26).
Error bars represent the s.e.m. for all xenografts used. ***Po0.0001, comparing to shControl via Student’s t-test. (i) Assessment of xenograft metastasis to
liver by human Alu PCR, which detects the human cancer cells in the mouse liver. Error bars represent the s.e.m. for three biological replicates. **Po0.001
comparing with shControl via Student’s t-test. NS, not significant.
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survival in this cohort, however, will likely require more robust
and longer-term clinical curation of the TCGA breast samples.
We then studied the role of DSCAM-AS1 on oncogenic
phenotypes in ER-positive breast cancer cell lines. In MCF7 and
T47D cells, stable knockdown of DSCAM-AS1 was achieved using
shRNA approaches. DSCAM-AS1 knockdown reduced the
proliferative ability of both cell lines (Fig. 3d), diminished the
ability of these cells to invade in a Boyden chamber invasion assay
(Fig. 3e), and substantially abolished the ability of these cells to
form colonies in soft agar (Fig. 3f). While ER regulates levels of
DSCAM-AS1, ER expression and protein levels are not dependent
on level of DSCAM-AS1 (Supplementary Fig. 4a), ruling out the
possibility that the phenotype observed could be explained
through changes in the level of ER. In addition, knockdown of
DSCAM-AS1 exhibited no affect on RNA or protein levels of the
DSCAM gene, in which DSCAM-AS1 resides antisense and
intronic (Supplementary Fig. 4b). To further demonstrate the
impact of DSCAM-AS1 on aggressive cancer phenotypes, we
overexpressed DSCAM-AS1 in T47D (Supplementary Fig. 4c) and
ZR75-1 (Supplementary Fig. 4d), two ER-positive breast cancer
cell lines with moderate DSCAM-AS1 expression (Fig. 2c), and
observed an increase in the invasion phenotype (Fig. 3g and
Supplementary Fig. 4e). MCF7 cells were not included in the
overexpression studies as DSCAM-AS1 is already expressed at a
very high level in these cells (Fig. 2c). Overexpression was also
tested in MDA-MB-231 cells (Supplementary Fig. 4f), a common
ER-negative cell line. However, exogenous DSCAM-AS1 was
unable to confer oncogenicity via proliferation (Supplementary
Fig. 4g) and invasion (Supplementary Fig. 4h). This phenomenon
may be explained by a requisite genetic and epigenetic milieu
provided by ER-positive cells in order for DSCAM-AS1 to confer
its cancer phenotype, and more investigation into the precise
mechanisms through which it acts will shed light on this finding.
Furthermore, the simple presence of DSCAM-AS1 alone is not
sufficient to make cells highly aggressive, as evidenced by its high
expression in ER-positive cell lines that are moderately invasive
(for example, MCF7). To further characterize the impact of
DSCAM-AS1 on cancer phenotype, we performed a mouse
xenograft tumour growth assay, showing that loss of DSCAM-AS1
reduces the growth of implanted T47D cells in vivo (Fig. 3h). The
metastatic potential of these implanted cells were also reduced
with DSCAM-AS1 knockdown, as evidenced through decreased
liver metastasis following xenograft (Fig. 3i).
Role of hnRNPL in DSCAM-AS1 mechanism. LncRNAs have
been shown to be functional through their binding interactions
with other RNAs, DNA, and with proteins2. Thus, identifying
protein binding partners for DSCAM-AS1 is a crucial step
in determining the mechanism through which it confers
oncogenicity. To identify DSCAM-AS1 binding partners, we
performed pull-down of DSCAM-AS1 and performed mass
spectrometry on the pull-down product to identify proteins
bound to DSCAM-AS1 (Fig. 4a). The protein hnRNPL was
observed to have the highest spectral counts for the sense form of
DSCAM-AS1 with zero spectral counts in the antisense pull-down
(Fig. 4b). In addition, PCBP2, a protein known to complex
with hnRNPL43, was also among the top proteins bound to
DSCAM-AS1. We thus investigated the interaction between
DSCAM-AS1 and hnRNPL further. HnRNPL is a protein
widely expressed in many tissue types (Supplementary Fig. 5a)
and has been implicated in regulating RNA stability and
processing with subsequent effects on gene expression44–47.
The binding of hnRNPL to DSCAM-AS1 was confirmed by
RNA pull-down followed by western blot, with no binding of
hnRNPL to the negative control antisense transcript (Fig. 4c).
Other RNA-binding proteins did not bind DSCAM-AS1,
however, suggesting that DSCAM-AS1 does not promiscuously
bind to RNA-binding proteins in general (Fig. 4c). To
further confirm this binding interaction and its specificity, RNA
immunoprecipitation (RIP) was performed with using antibodies
directed against hnRNPL. DSCAM-AS1 was highly enriched by
anti-hnRNPL RIP in both MCF7 and T47D cells, while control
coding and noncoding genes exhibited modest binding (Fig. 4d).
In addition, anti-snRNP70 and anti-HuR RIP failed to pull-down
DSCAM-AS1, further suggesting the specificity of the
DSCAM-AS1-hnRNPL interaction (Supplementary Fig. 5b).
To more specifically investigate the functional relationship of
DSCAM-AS1 and hnRNPL, we performed rescue studies
assessing the impact of hnRNPL knockdown on the invasive
advantage conferred by DSCAM-AS1 overexpression, observing
that reduction of hnRNPL levels entirely reversed the increase in
invasion observed on DSCAM-AS1 overexpression (Fig. 4e,
Supplementary Fig. 6a). Because there was only slight, non-
significant reduction in invasion with hnRNPL knockdown in
control cells, the marked reduction in invasion observed in the
DSCAM-AS1 overexpressing cells with hnRNPL knockdown may
be the result of hnRNPL affecting invasion in a mechanism
exclusive to DSCAM-AS1. So, to further characterize the
functional relationship between DSCAM-AS1 and hnRNPL, we
set out to localize the binding site of hnRNPL within the DSCAM-
AS1 lncRNA. Using in silico prediction drawing from prior
studies of hnRNPL crosslinking-immunoprecipitation sequencing
(CLIP-seq)48, a single strong predicted binding peak was
identified near the 30-end of DSCAM-AS1 (Fig. 4f). HnRNPL
has been shown to bind CACA-rich RNA sites45, and the
predicted binding region possessed a 10 base pair CACA stretch.
To identify if this predicted region does in fact account for the
hnRNPL binding, multiple mutant forms of DSCAM-AS1 were
created with or without the binding site. DSCAM-AS1-5 and
DSCAM-AS1-3 are large deletion mutants containing only the
50- and 30-end, respectively, with only DSCAM-AS1-3 possessing
the predicted binding site, and DSCAM-AS1-D is a mutant form
with the 27 nucleotides comprising the predicted binding site
deleted (Fig. 4f,g, red). The various mutant forms of DSCAM-AS1
were expressed in HEK293, a cell line that lacks endogenous
DSCAM-AS1 expression while still expressing hnRNPL
(Supplementary Fig. 6b). While both the full-length and
DSCAM-AS1-3 mutant retained hnRNPL binding, loss of the
predicted binding region was effective in abrogating hnRNPL
binding via both Western blot following RNA pull-down (Fig. 4g)
and by qPCR following hnRNPL RIP (Supplementary Fig. 6c). All
deletion mutants were expressed at comparable levels, ruling out
the possibility of falsely diminished binding due to failed
expression of the mutant construct (Supplementary Fig. 6d).
RNA secondary structure is a crucial component of RNA
functionality and is a key player in RNA-protein interactions.
While the 27 nucleotide deletion in the DSCAM-AS1-D mutant is
a small fraction of the total number of bases in the transcript,
to ensure that this deletion was not causing a marked RNA
secondary structure change, we investigated the impact of this
deletion on RNA secondary structure via the RNAfold structure
prediction tool49. Evidenced by a minimal free energy prediction,
the posited secondary structure of DSCAM-AS1 is largely
similar to that of DSCAM-AS1-D (Supplementary Fig. 6e),
suggesting that the loss of hnRNPL binding observed with the
DSCAM-AS1-D mutant is not due to a dramatic secondary
structure rearrangement. Quite interestingly, overexpression of
the DSCAM-AS1-Dmutant in T47D cells failed to recapitulate the
increased invasion observed when overexpressing full-length
DSCAM-AS1 (Fig. 4h). This finding, in combination with the
rescue studies following hnRNPL knockdown (Fig. 4e), strongly
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suggest that DSCAM-AS1 promotes oncogenicity via its
interaction with hnRNPL in these ER-positive breast cancer cells.
Role of DSCAM-AS1 in tamoxifen resistance. A substantial
number of patients with ER-positive breast cancer eventually
develop resistance to endocrine therapy and present with clinical
recurrence and metastasis11,50,51. Thus, as DSCAM-AS1 is
implicated in poor-prognosis ER-positive breast cancer (Fig. 3a-c
and Supplementary Fig. 3), we set out to investigate its potential
role in subverting oestrogen dependence and promoting
resistance to anti-oestrogen therapies. We continuously
passaged MCF7 cells in 1 uM tamoxifen for 6 months until we
attained a subpopulation of MCF7 cells that were able to grow in
in tamoxifen and termed these tamoxifen-resistant MCF7 cells
(TamR-MCF7). Interestingly, although expression of canonical
ER targets (GREB1 and PGR) was decreased compared to the
parental MCF7 cells, DSCAM-AS1 expression was significantly
upregulated despite already being expressed at very high levels in
MCF7 cells (Fig. 5a). The levels of ER were also increased, which
is likely a compensatory upregulation in response to the continual
anti-oestrogen effects of tamoxifen. Additionally, short-term
tamoxifen treatment of parental MCF7 cells transiently reduced
DSCAM-AS1 levels at 8hrs following tamoxifen treatment, with a
rise back to pre-treatment levels after 24 h (Supplementary
Fig. 7a). In contrast, canonical ER target, GREB1, exhibited
pronounced expression reduction at both the short- and long-
term timescale (Supplementary Fig. 7b). To interrogate whether
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this upregulation of DSCAM-AS1 in the TamR-MCF7 cells is
functionally significant, we assessed the proliferative capacity of
these cells following DSCAM-AS1 knockdown. With knockdown
levels of DSCAM-AS1 comparable to the endogenous levels in
parental MCF7 cells (Supplementary Fig. 7c), knockdown of
DSCAM-AS1 in TamR-MCF7 cells led to a loss of their baseline
proliferative advantage when cultured in tamoxifen, exhibiting a
proliferation profile nearly identical to that of the parental MCF7
cells (Fig. 5b). Additionally, knockdown of hnRNPL in these
cells produced a similar loss of proliferative capacity in the
TamR-MCF7 cells (Supplementary Fig. 7d,e), suggesting that
both DSCAM-AS1 and hnRNPL may be playing a role in
promotion of the tamoxifen resistance developed by these cells.
We also interrogated the ability of DSCAM-AS1 to confer
tamoxifen resistance in native T47D cells via overexpression of
DSCAM-AS1. DSCAM-AS1 overexpression was also associated
with tamoxifen-resistant growth in a dose-dependent manner,
with a striking increase in cell viability at levels of tamoxifen as
low was 100 nM (Fig. 5c). Additionally, in line with the ability
of DSCAM-AS1 to provide oestrogen-independent growth
advantage, cells overexpressing DSCAM-AS1 also exhibited a
proliferative advantage when grown in oestrogen-deprived
medium compared to normal serum (Supplementary Fig. 7f).
This growth advantage was abolished with the addition
of oestrogen, and returned with the subsequent addition of
tamoxifen (Supplementary Fig. 7f). Conversely corroborating the
relationship of DSCAM-AS1 on oestrogen dependence in these
cells, we witnessed an increased oestrogen dependence of T47D
cells following DSCAM-AS1 knockdown (Supplementary Fig. 7g).
To corroborate our in vitro findings in a tissue model, we
obtained data previously generated performing ChIP-seq for ER
in primary and metastatic breast tumour tissue13. These tumours
were grouped into the following categories as previously
described13: primary ER-negative (n¼ 2), primary ER-positive,
tamoxifen-responder (n¼ 8), primary ER-positive, tamoxifen-
non-responder (n¼ 7), metastatic ER-positive (n¼ 3). Strikingly,
investigation of the DSCAM-AS1 promoter revealed that
ER preferentially binds to the DSCAM-AS1 promoter in
tumours with clinical aggression (ie, metastatic and tamoxifen
non-responders; Fig. 5d), while a canonical ER target, GREB1,
exhibits ER-biding to its promoter in nearly all ER-positive
tumours, lacking preference for the more clinically aggressive
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tumours. Altogether, these data suggest that the association
between DSCAM-AS1 expression with clinical aggressiveness in
ER-positive breast cancer samples may be explained, in part, by
the ability of DSCAM-AS1 to facilitate oestrogen-independent
oncogenicity, thus potentially promoting resistance to endocrine
therapy with tamoxifen.
Discussion
Further investigation and study of the mechanisms through
which ER-dominant breast cancers become aggressive and
eventually evade traditional clinical therapies is of intense clinical
interest. In this study, we identify a myriad of potentially
ER-associated lncRNAs, and functionally and mechanistically
characterize one of the most intriguing candidates. Nevertheless,
further investigation of some of these other lncRNAs may also
contribute to our understanding of ER biology and ER-driven
oncogenesis. LncRNAs have been shown to function through
multiple mechanisms, and the study of the interaction of
DSCAM-AS1 with hnRNPL is a promising step towards under-
standing the ways through which this molecule executes its
oncogenic function. While we show that the binding of hnRNPL
to DSCAM-AS1 is responsible for at least some of its
oncogenicity, a further understanding of how the interaction
between hnRNPL and DSCAM-AS1 is mediating this phenotype
is necessary.
Novel mediators of tumour aggression, such as DSCAM-AS1,
can provide insight into the mechanism of endocrine therapy
resistance. This increased understanding may in turn lead to
more effective strategies to overcome this resistance, which is one
of the last, great clinical challenges in treatment of ER-positive
breast cancer. In addition, there is little known regarding the role
of noncoding RNAs in developing resistance to anti-oestrogen
therapy, with a small number of studies implicating some of the
more prominent, well characterized breast cancer lncRNAs52,53.
DSCAM-AS1 is just one of many potentially relevant ER-
regulated lncRNAs in breast cancer, and further investigation of
the other candidates is likely to yield a greater understanding of
ER-mediated cancer biology. Ultimately, this study provides key
insight into the role of lncRNAs in ER breast cancer biology, and
is an important step in better understanding this common
disease.
Methods
Cell lines and cell culture. All cell lines were obtained from the American Type
Culture Collection (Manassas, VA). Cell lines were maintained using standard
media and conditions. Specifically, T47D cells were maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine
serum, 1% penicillin-streptomycin and 5mgml 1 insulin. ZR75-1 cells were
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1%
penicillin-streptomycin. HEK293 cells were maintained in DMEM plus 10% fetal
bovine serum (FBS) plus 1% penicillin-streptomycin. MCF7 cells were cultured in
Dulbecco’s modified Eagle’s medium plus GlutaMAX (DMEM, Invitrogen)
containing 10% fetal bovine serum (Hyclone) and 1% penicillin-streptomycin.
To establish the tamoxifen-resistant cell line, MCF7 cells were grown in IMEM
phenol-red free medium with 10% Charcoal-stripped FBS in the presence of 1 uM
(Z)-4-hydroxytamoxifen (Sigma) for 6 months. All cell lines were grown at 37 C in
a 5% CO2 cell culture incubator, and were genotyped for identity at the University
of Michigan Sequencing Core and tested routinely for Mycoplasma contamination.
Cell proliferation assay. Cells were seeded in a 48-well plate at 3 104 cells per
well. Plates were added to Incucyte machine (Essen Bioscience) 16–20 h following
seeding. Growth curves were constructed by imaging plates using the Incucyte
system, where the growth curves are generated from confluence measurements
acquired during continuous kinetic imaging. Four wells were measured per
condition. For tamoxifen treatment, 16–20 h after seeding, the medium was
changed to RPMI phenol-red free medium containing 10% charcoal-treated FBS in
the presence of 1 uM tamoxifen or ethanol. Growth curves were obtained using
Incucyte system as described above.
Cell viability assay. Cells were seeded in 96-well plates at 5,000 cells per well in a
total volume of 100 ml media containing 10% FBS. Serially diluted tamoxifen in
100 ml of media was added to the cells 12 h after seeding. Medium containing
tamoxifen was replenished every 2–3 days. Following 10 days of incubation, cell
viability was assessed by WST assay (WST-8, Dojindo). All assays were performed
in triplicate and repeated at least three times. The relative cell viability was
expressed as a percentage of the control that was treated with vehicle solutions.
Soft agar colony formation assay. 10,000 cells were suspended in medium
containing 0.3% agar, 10% FBS, and layered on medium containing 0.6% agar and
10% FBS in six-well plate. Colonies were stained for 18–24 h with iodonitrote-
trozolium chloride (Sigma #18377) following 3 weeks of incubation. Colonies from
three replicate wells were quantified.
Quantitative RT–PCR assay. The miRNeasy mini kit was utilized to isolate RNA
from cell lysates. From 1 mg of isolated RNA, SuperScript III (Invitrogen) and
Random Primers (Invitrogen) were used to generate cDNA according to the
manufacturer’s protocol. The ABI7900 HT Fast Real time system (Applied
Biosystems) was utilized for quantitiative reverse transcriptase–PCR (qRT–PCR)
reactions. Gene-specific primer were designed using the Primer3 software and were
subsequently synthesized by IDT Technologies. A relative quantification method
was used in analysing the qRT–PCR data and data were depicted as average fold
change versus the control (as internal reference, GAPDH and actin were utilized).
All primers used for qPCR are detailed in Supplementary Table 2. Three technical
replicates were used in each assay, and all data shown was performed with at least
three biological replicates.
Oestrogen and tamoxifen treatment. To evaluate the effect of oestrogen
stimulation, cells were first hormone depleted via growth in phenol-red free
medium containing 10% charcoal-treated FBS for 72 h and then treated with
ethanol vehicle, 10 nM b-estradiol, or 10 nM b-estradiol plus 1 uM tamoxifen. After
10 h, RNA was isolated as described above and qPCR was performed as described
above using Power SYBR Green Mastermix (Applied Biosystems).
Subcellular fractionation. Cellular fractionation was performed using a RiboTrap
Kit (MBL International), according to manufacturer’s instructions. RNA was
isolated and qRT–PCR was performed as described above.
Knockdown and overexpression studies. Knockdown of DSCAM-AS1 and
hnRNPL in T47D and MCF7 cells was accomplished by small interfering RNA
from Dharmacon. Transfections were performed with OptiMEM (Invitrogen) and
RNAi Max (Invitrogen) per manufacturer instruction. Target sequences used for
shRNA or small interfering RNA knockdown are listed in Supplementary Table 3.
For stable knockdown of DSCAM-AS1, MCF7 and T47D cells were transfected
with lentiviral constructs containing 2 different DSCAM-AS1 shRNAs or no
targeting shRNAs in the presence of polybrene (8 mgml 1 Supplementary
Table 3). After 48 h, transduced cells were grown in culture media containing
2 mgml 1 puromycin.
For DSCAM-AS1 overexpression, the predominant isoform (isoform 2,
Supplementary Table 1) was cloned into the pLenti6.3 vector (Invitrogen) using
PCR8 non-directional Gateway cloning (Invitrogen) as an initial cloning vector and
shuttling was then done to pLenti6.3 using LR clonase II (Invitrogen) according to
the manufacturer’s instructions. As control, LacZ was also cloned into the same
vector system. The primers for making DSCAM-AS1 mutation and truncations are
listed in Supplementary Table 2. Lentiviral particles were made and T47D and
ZR75.1 cells were transduced as described above. Stable cell lines were generated by
selection with 3 mgml 1 blasticidin. Transient transfection of DSCAM-AS1 and its
derivative mutants was done in HEK293 cells was performed with Lipofectamine
LTX (Invitrogen) following manufacturer’s instruction. Cells were collected at 48 h
post transfection.
In vitro RNA-binding assay. The RNA-binding assay was performed according to
the protocol of the RiboTrap Kit (MBL International). In brief, 5-bromo-UTP
(BrU) was randomly incorporated into sense DSCAM-AS1, antisense DSCAM-AS1,
and LacZ control via PCR-based transcription. The primers are shown in
Supplementary Table 2. The the BrU labelled RNA transcripts were bound to beads
conjugated with anti-BrdU antibodies. Then, the cytoplasmic or nuclear fractions
from MCF7 or T47D cells were mixed for 2 h. Samples were washed four times
with Wash Buffer II before elution. The samples were sent to the Michigan Center
for Translational Pathology proteomic core facility for mass spectrometry.
Mass spectrometry. The samples were treated with SDS-PAGE loading buffer
supplied with 10mM DTT for 5min at 85 C. The proteins were alkylated by the
addition of iodoacetamide to the final concentration of 15mM. The samples were
subjected to SDS–PAGE and the whole lanes were cut out and digested with trypsin
in-gel for 2 h. The resulting peptides were extracted, dried and resuspended in 0.1%
formic acid with 5% acetonitrile before loading onto a 2 cm EASY-column
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(Thermo Scientific) coupled to an in-house made nano HPLC column (20 cm 
75 um) packed with LUNA C18 media (Phenomenex). Analysis was performed on
a Velos Pro mass spectrometer (Thermo Scientific) operated in data-dependent
mode using 120-min gradients in EASY-LC system (Proxeon) with 95% water, 5%
acetonitrile (ACN), 0.1% formic acid (FA) (solvent A), and 95% ACN, 5% water,
0.1% FA (solvent B) at a flow rate of 220 nlmin 1. The acquisition cycle consisted
of a survey MS scan in the normal mode followed by 12 data-dependent MS/MS
scans acquired in the rapid mode. Charge state was not recorded. Dynamic
exclusion was used with the following parameters: exclusion size 500, repeat count
1, repeat duration 10 s, exclusion time 45 s. Target value was set at 104 for tandem
MS scan. The precursor isolation window was set at 2m/z. The complete analysis
comprised two independent biological replicates.
Mass spectrometry data analysis. The resulting spectrum files were transformed
into MGF format by MSConvert software and interrogated by MASCOT 2.4 search
engine using human UniProt database version 15 concatenated with reverse
sequences for estimation of false discovery rate (FDR) and with a list of common
contaminants (40,729 entries in total). The search parameters were as follows: full
tryptic search, 2 allowed missed cleavages, peptide charges þ 2 and þ 3 only,
MS tolerance 1Da, MS/MS tolerance 0.5Da. Permanent post-translational
modification was: cysteine carbamidomethylation. Variable post-translational
modifications were: protein N-terminal acetylation, Met oxidation and N-terminal
Glutamine to pyro-Glutamate conversion. The remaining analysis was performed
as previously described54. To summarize, the minimal ion score threshold was
chosen such that a peptide FDR below 1% was achieved. The peptide FDR was
calculated as: 2 (decoy_hits)/(targetþ decoy hits). The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium55
via the PRIDE partner repository with the data set identifier PXD002421 and
10.6019/PXD002421. Spectral counts for all detected proteins were assembled using
an in-house written Python script. The adjustment of spectral counts was done as
previously described54.
RNA immunoprecipitation. RIP assays were performed using a Millipore
EZ-Magna RIP RNA-Binding Protein Immunoprecipitation kit (Millipore,
#17-700) according to the manufacturer’s instructions. RIP-PCR was performed as
qPCR, as described above, using total RNA as input controls. 1:150th of RIP RNA
product was used per PCR reaction. Antibodies used for RIP are listed in
Supplementary Table 4. All RIP assays were performed in biological duplicate.
Invasion assay. 3 105 cells were seeded in a 24-well corning FluoroBlok
chamber pre-coated with Matrigel (BD Biosciences). Medium containing 10% FBS
in the lower chamber served as chemoattractant. After 48 h, cells remaining on the
lower side of the membrane were stained with calcein AM (C34852 invitrogen).
The invasive cells adhering to the bottom surface of the filter were quantified under
a fluorescent microscope ( 2).
Antibodies and immunoblot analyses. Western immunoblot assays were
performed by running cell lysates on 4–12% SDS polyacrylamide gels (Novex) to
separate proteins. Proteins were then transferred to a nitrocellulose membrane
(Novex) via wet transfer at 30V overnight. Blocking buffer incubation was then
performed for 1 h (Tris-buffered saline, 0.1% Tween (TBS-T), 5% nonfat dry milk).
Indicated antibodies were then added to membrane and incubated at 4 C
overnight. Enhanced chemiluminescence (ECL Prime) was utilized to develop blots
via the manufacturer’s protocol. All the antibodies used in this study are described
in Supplementary Table 4. Representative full blot images are shown in
Supplementary Fig. 8.
Chromatin immunoprecipitation. HighCell# ChIP kit (Diagenode) was utilized to
perform ChIP assays via the manufacturer’s protocol. Briefly, MCF7 cells were
grown in charcoal-stripped serum media (described above) for 72 h and then
stimulated 10 nM estradiol for 12 h. Cells were then crosslinked using 1%
formaldehyde for 10min, and crosslinking was quenched for 5min at room
temperature using a 1/10 volume of 1.25M glycine. Cells were then lysed and
sonicated (Bioruptor, Diagenode), yielding an average chromatin fragment size of
300 bp. An equivalent amount of chromatin equivalent to 5 106 cells was used for
the ChIP for all antibodies. DNA bound to immunoprecipitated product was
isolated (IPure Kit, Diagenode) via overnight incubation with antibody at 4 C.
Samples were then washed, and crosslinked reversed.
ChIP-seq library construction and sequencing analysis. DNA was purified
for library preparation using the IPure Kit (Diagenode). The ChIP-seq sample
preparation for sequencing was performed according to the manufacturer’s
instructions (Illumina). ChIP-enriched DNA samples (1–10 ng) were converted
into blunt-ended fragments using T4 DNA polymerase, Escherichia coli DNA
polymerase I large fragment (Klenow polymerase) and T4 polynucleotide kinase
(New England BioLabs (NEB)). A single adenine base was added to fragment ends
by Klenow fragment (30 to 50 exo ; NEB) followed by ligation of Illumina adaptors
(Quick ligase, NEB). The adaptor-modified DNA fragments were enriched by PCR
using the Illumina Barcode primers and Phusion DNA polymerase (NEB). PCR
products were size selected using 3% NuSieve agarose gels (Lonza) followed by gel
extraction using QIAEX II reagents (QIAGEN). Libraries were quantified with the
Bioanalyzer 2100 (Agilent) and sequenced on the Illumina HiSeq 2000 Sequencer
(100-nucleotide read length). ChIP-seq data were mapped to human genome
version hg19 using BWA56. The MACS program57 was used to generate coverage
map files to visualize the raw signal on the UCSC genome browser58. Hpeak59,
a hidden Markov model (HMM)-based peak-calling software program designed for
the identification of protein-interactive genomic regions, was used for ChIP-seq
peak determination.
ChIP-seq peak promoter overlap. Overlap of ChIP-seq peaks with gene
promoters was performed using the BEDTools ‘coverage’ tool. Intervals of±5–10
kilobases surrounding unique transcriptional starts were used to assess promoter
overlap.
Coding potential scoring. Coding potential for all lncRNA transcripts was
determined as described previously4. The alignment-free Coding Potential
Assessment Tool (CPAT)25 was used to determine coding probability for each
transcript. CPAT determines the coding probability of transcript sequences using a
logistic regression model built from ORF size, Fickett TESTCODE statistic, and
hexamer usage bias.
Xenograft analysis. All experimental procedures were approved by the University
of Michigan Committee for the Use and Care of Animals (UCUCA) and conform
to all regulatory standards. A total of 5 106 cells of T47D control or T47D shM41
cells were suspended in 100 ul of PBS/Matrigel (1:1) were injected subcutaneously
in 5-week-old pathogen-free female CB-17 severe combine immunodefiecient mice
(CB-17 SCID) which simultaneously received a 60-day slow release pellet con-
taining 0.18mg of 17b-estradiol (Innovative Research of America). Tumours were
measured weekly using a digital caliper. Growth in tumour volume was recorded
using digital calipers and tumour volumes were estimated using the formula (p/6)
(LW2), where L¼ length of tumour and W¼width. In addition, mouse livers
were collected to determine spontaneous metastasis by measuring human Alu
sequence. Briefly, genomic DNA from livers were prepared using Puregene DNA
purification system (Qiagen), followed by quantification of human Alu sequence by
human Alu specific Fluorogenic Taqman qPCR probes.
RNA-seq data processing. Sequence quality control was done using FASTQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Next, reads mapping
to mitochondrial DNA, ribosomal RNA, poly-A, poly-C, Illumina sequencing
adaptors, and the spiked-in phiX174 viral genome were filtered. Sequences were
downloaded from the Illumina iGenomes server (2012, March 9). Mapping was
performed using bowtie2 (2.0.2). Reads were mapped using TopHat2 (2.0.6 and
2.0.8) using default parameters. A human genome reference was constructed
from UCSC version Feb 2009 (GRCh37/hg19) chromosomes 1–22, X, Y and
mitochondrial DNA, and references from alternate haplotype alleles were omitted.
Bowtie-build and bowtie2-build were used to build genome reference for Bowtie
versions 0.12.8 and 2.0.2 were, respectively. The Ensembl version 69 transcriptome
was used as a reference gene set. Using the --transcriptome-index option in TopHat
version 2.0.6 (ref. 60), alignment index files were prepared from this reference for
Bowtie versions 0.12.8 and 2.0.2.
RNA-seq transcript expression estimation. Cufflinks version 2.1.1 (ref. 61)
was used with the following parameters to estimate transcript abundance from
RNA-seq data: ‘--max-frag-multihits¼ 1’, ‘--no-effective-length-correction’,
‘--max-bundle-length 5000000’, ‘--max-bundle-frags 20000000’. To convert FPKM
abundance estimates (generated by Cufflinks) to approximate fragment count
values we multiplied each FPKM by the transcript length (in kilobases) and by the
‘Map Mass’ value (divided by 1.0E6) found in the Cufflinks log files.
Breast cancer tissue expression heatmap generation. The ‘gplots’ R-package
was used to generate heatmaps using the heatmap.2 function. For the cancer versus
normal heatmap, expression was normalized as log2 of the fold change over the
median of the normal samples for each transcript. For the ER-positive versus
ER-negative heatmap, expression was normalized to the median of the ER-negative
samples. Unsupervised heirarchical clustering was performed with the hclust
function, using Pearson correlation as the clustering distance, using the ‘ward’
agglomeration method.
RNA-seq differential expression testing. Differential expression testing was
performed using the SSEA tool described previously7. Briefly, following count data
normalization, SSEA performs the weighted KS-test procedure described in
GSEA42. The resulting enrichment score statistic describes the enrichment of the
sample set among all samples being tested. To test for significance, SSEA
enrichment tests are performed following random shuffling of the sample labels.
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These shuffled enrichment tests are used to derive a set of null enrichment scores
(1,000 null enrichment scores computed). The nominal P value reported is the
relative rank of the observed enrichment score within the null enrichment scores.
Multiple hypothesis testing is performed by comparing the enrichment score of the
test to the null normalized enrichment score distributions for all transcripts in a
sample set. This null normalized enrichment score distribution is used to compute
FDR Q values in the same manner used by GSEA42.
Associations with oncomine clinical signatures. We identified the top 150
positively and negatively correlated genes (Spearman’s correlation) to DSCAM-AS1
among the ER-positive breast cancer samples. These gene lists were imported into
Oncomine27 as custom concepts. We then nominated significantly associated
breast cancer concepts with odds ratio44.0 for negatively associated concepts and
46.0 for positively associated concepts and P value o1 10 6. Nodes and edges
of these associations were exported and a concept association network was
generated using Cytoscape version 3.2.1. Node positions were computed using the
Force-Directed Layout algorithm in Cytoscape using the odds ratio as the edge
weight. Node positions were subtly altered manually to enable better visualization
of node labels.
Association of correlation signatures with oncomine concepts. Correlation
analysis described above was performed for DSCAM-AS1, EZH2, HOTAIR,
MALAT1, and NEAT1. For each gene, we created a signature of the top 150 most
positively and top 150 most negatively correlated genes. We performed a Fisher’s
exact test of overlap for each of the above gene signatures with Oncomine clinical
signatures for cancer versus normal, clinical recurrence, clinical survival, metas-
tasis, and high clinical grade. The following studies were utilized: Curtis Breast26,
Ma Breas62, TCGA Breast28, Zhao Breast29, Bittner Breast63, Desmedt Breast30,
Ivshina Breast31, Loi Breast32, Lu Breast33, Perou Breast22, Schmidt Breast34,
Sorlie Breast23, vantVeer Breast64, Wang Breast36, Boersma Breast37, Kao Breast38,
Symmans Breast39 and vandeVijver Breast40. For each Oncomine concept, overlap
was tested for the top 1, 5 and 10% of genes up- and downregulated, and the gene
signature with the greatest odds ratio was selected for each study. Signature
comparisons were performed using a one-sided Fisher’s exact test.
Survival analysis with TCGA breast data. Association of DSCAM-AS1 levels on
clinical outcomes was assessed using the TCGA breast cohort. Survival data was
obtained from the TCGA data portal. ER-positive samples were used for survival
analysis as indicated by the TCGA clinical metadata via IHC status. Samples
with DSCAM-AS1 expression 410 FPKM were grouped into the ‘DSCAM-AS1
high’ category and samples with expression o1 FPKM were grouped into the
‘DSCAM-AS1 low’ category. Kaplan-Meier analysis was performed, and log-rank
test was performed to assess statistical significance.
Tissue expression level percentile metric. To generate a metric to summarize
the expression of each lncRNA in breast cancer tissues, we identified the expression
level of the 95th percentile sample among all breast RNA-seq samples including
cancers tissue, normal tissue, and cell lines.
RNA-sequencing library preparation. Total RNA was obtained from cancer cell
lines, and RNA quality was determined using an Agilent Bioanalyzer. Poly-A
transcriptome libraries from the mRNA fractions were generated following the
Illumina RNA-seq protocol. Each sample was sequenced in a single lane with the
Illumina HiSeq 2000 (100-nucleotide read length) as previously described3,65.
The dUTP method of second-strand marking was used for strand-specific library
preparation as described previously66.
Gene set enrichment analysis. Expression levels of DSCAM-AS1 were correlated
(Spearman) to the expression of all protein-coding genes across all ER-positive
breast cancers. The protein-coding genes were then ranked by the Spearman Rho
value, and used in a weighted, preranked GSEA analysis against MSigDB gene sets
V5.0 (ref. 67).
In silico binding prediction. To obtain potential HNRNPL binding sites
on DSCAM-AS1, we utilized GraphProt68 to learn a predictive model from
genome-wide HNRNPL binding sites identified by iCLIP-seq48. For training data
generation, we extracted the genomic binding positions (GSE37560) with BED
table scores 4¼ 10, followed by an extension of ±20 nt resulting in 41 nt long
binding sites. After mapping the sites to annotated RefSeq genes obtained from
UCSC, an equally-sized set of negative sites was selected such that the sites were on
the same RefSeq genes and did not overlap with any of the identified positive sites
from the initial table. The GraphProt sequence model trained on these data was
then used to identify high-scoring sites in the DSCAM-AS1 sequence (NCBI
GenBank NR_038899.1). The highest-scoring site centred at RNA position 923
contains a CA-repeat motif known for its affinity towards HNRNPL and was thus
used for subsequent analysis.
Rapid amplification of cDNA ends (RACE). 50 and 30 RACE was performed
using the GeneRacer RLM-RACE kit (Invitrogen) according to the manufacturer’s
protocols. RACE PCR products obtained using Platinum Taq high-fidelity
polymerase (Invitrogen), were resolved on a 1.5% agarose gel. Individual bands
were gel purified using a Gel Extraction kit (Qiagen), and cloned into PCR4 TOPO
vector, and sequenced using M13 primers.
Single-molecule fluorescence in situ hybridization. Single-molecule fluorescence
in situ hybridization was performed as described69, with some minor
modifications. Cells were grown on 8-well chambered coverglasses, formaldehyde
fixed and permeablized overnight at 4 oC using 70% ethanol. Cells were rehydrated
in a solution containing 10% formamide and 2 SSC for 5min and then treated
with 10 nM fluorescence in situ hybridization probes for 16 h in 2 SSC containing
10% dextran sulfate, 2mM vanadyl-ribonucleoside complex, 0.02% RNAse-free
BSA, 1 mgml 1 E. coli transfer RNA and 10% formamide at 37 C. After
hybridization, cells were washed twice for 30min at 37 C using a wash buffer
(10% formamide in 2 SSC). Cells were then mounted in solution containing
10mM Tris/HCl pH 7.5, 2 SSC, 2mM trolox, 50 mM protocatechiuc acid and
50 nM protocatechuate dehydrogenase. fluorescence in situ hybridization samples
were imaged in three dimensions using HILO illumination as described70. Images
were processed using custom-written macros in ImageJ. Analysis routines
comprises 3 major steps: background subtraction, Laplacian of Gaussian (LoG)
filtering and thresholding. Spots with intensity above set threshold are represented
in images. Probes were designed to target all isoforms of the DSCAM-AS1
transcript. Probe sequences targeting DSCAM-AS1 (21 probes per transcript) are
as follows: 50-cctatccctttctctaagaa-30 , 50-acttctgcaaaaacgtgctg-30 , 50-ggttccactccatt
ttaatt-30 , 50-ctatagcgtcttatcagctg-30 , 50-catgtgtccggatatcattt-30 , 50-tcagtgagtggataact
ggt-30 , 50-aattctagtggaggcaccta-30 , 50-ctaagtagcttcatctttcc-30 , 50-caactgcgtgtttccta
gtc-30, 50-agcattctctgttttaacca-30 , 50-ttagcaactgccttgctctg-30 , 50-gctgtccagttttagta
aca-30 , 50-cgttgtgagcctgagagatc-30 , 50-agaacttccctagaggagtg-30 , 50-atggggagtgagaccaa
aca-30 , 50-tggaggagggacagagaagg, 50-tgtgggtgattggtactttt-30 , 50-atggatgagtatgtcat
gcc-30 , 50-tattgccatggttagcatga-30 , 50-aatgcatgcttgatggagct-30.
Data availability. Sequence data that support the findings of this study have been
deposited in the Short Read Archive with the accession code SRP078392. Tissue
ChIP-seq data referenced in this study are available in the Gene Expression
Omnibus with the accession code GSE32222. All remaining data are contained
within the Article and Supplementary Information files or available from the
author on request.
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